Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Rifampin and Itraconazole on Zanubrutinib PK in Healthy Subjects
NCT03301181Phase 1Completed
- Sponsor
- BeiGene
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanubrutinib in B cell malignancies (2 arms), sponsored by BeiGene. Primary endpoints: Plasma concentration of BGB-3111 and rifampin to evaluate protocol specified PK parameters at Day 10 and Plasma concentration of BGB-3111 and itraconazole to evaluate protocol specified PK parameters at Day 6. Started Sep 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT03301181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301181.